Switch theme
Sign up to access all valuation multiples
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Planet, Investments, and others. The majority of its revenue is generated from the planet segment. The geographical segments are UAE, Other GCC countries, and Other countries.
1980
2.3K+
LTM Revenue $365M
LTM EBITDA $49.8M
$618M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Julphar has a last 12-month revenue of $365M and a last 12-month EBITDA of $49.8M.
In the most recent fiscal year, Julphar achieved revenue of $446M and an EBITDA of $31.3M.
Julphar expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Julphar valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $440M | $446M | XXX | XXX | XXX |
| Gross Profit | $104M | $136M | XXX | XXX | XXX |
| Gross Margin | 24% | 30% | XXX | XXX | XXX |
| EBITDA | $40.3M | $31.3M | XXX | XXX | XXX |
| EBITDA Margin | 9% | 7% | XXX | XXX | XXX |
| Net Profit | $17.5M | -$8.0M | XXX | XXX | XXX |
| Net Margin | 4% | -2% | XXX | XXX | XXX |
| Net Debt | $152M | $185M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Julphar's stock price is AED 1 (or $0).
Julphar has current market cap of AED 1.4B (or $377M), and EV of AED 2.3B (or $618M).
See Julphar trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $618M | $377M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Julphar has market cap of $377M and EV of $618M.
Julphar's trades at 1.7x LTM EV/Revenue multiple, and 12.4x LTM EBITDA.
Analysts estimate Julphar's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Julphar and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $618M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 19.8x | XXX | XXX | XXX |
| P/E | -14.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 34.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJulphar's NTM/LTM revenue growth is 8%
Julphar's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Julphar's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Julphar's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Julphar and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -22% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 15% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 36% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Julphar acquired XXX companies to date.
Last acquisition by Julphar was XXXXXXXX, XXXXX XXXXX XXXXXX . Julphar acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Julphar founded? | Julphar was founded in 1980. |
| Where is Julphar headquartered? | Julphar is headquartered in United Arab Emirates. |
| How many employees does Julphar have? | As of today, Julphar has 2.3K+ employees. |
| Is Julphar publicy listed? | Yes, Julphar is a public company listed on ADS. |
| What is the stock symbol of Julphar? | Julphar trades under JULPHAR ticker. |
| When did Julphar go public? | Julphar went public in 2002. |
| Who are competitors of Julphar? | Similar companies to Julphar include e.g. Galapagos, Pharming, Vivoryon Therapeutics, Armata Pharmaceuticals. |
| What is the current market cap of Julphar? | Julphar's current market cap is $377M |
| What is the current revenue of Julphar? | Julphar's last 12-month revenue is $365M. |
| What is the current EBITDA of Julphar? | Julphar's last 12-month EBITDA is $49.8M. |
| What is the current EV/Revenue multiple of Julphar? | Current revenue multiple of Julphar is 1.7x. |
| What is the current EV/EBITDA multiple of Julphar? | Current EBITDA multiple of Julphar is 12.4x. |
| What is the current revenue growth of Julphar? | Julphar revenue growth between 2023 and 2024 was 1%. |
| Is Julphar profitable? | Yes, Julphar is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
